Rudolf Herbst

4.3k total citations · 1 hit paper
70 papers, 1.9k citations indexed

About

Rudolf Herbst is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Rudolf Herbst has authored 70 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 19 papers in Molecular Biology and 14 papers in Immunology. Recurrent topics in Rudolf Herbst's work include Cutaneous Melanoma Detection and Management (17 papers), Melanoma and MAPK Pathways (11 papers) and Cancer Genomics and Diagnostics (10 papers). Rudolf Herbst is often cited by papers focused on Cutaneous Melanoma Detection and Management (17 papers), Melanoma and MAPK Pathways (11 papers) and Cancer Genomics and Diagnostics (10 papers). Rudolf Herbst collaborates with scholars based in Germany, United States and Austria. Rudolf Herbst's co-authors include Alexander Kapp, Claus Garbe, Carola Berking, Webster K. Cavenee, Karen C. Arden, Ulrike Leiter, Jens Ulrich, Percy Lehmann, Jan‐Christoph Simon and Rudolf Stadler and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and The Lancet Oncology.

In The Last Decade

Rudolf Herbst

66 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial

2016 405 citations Ulrike Leiter, Rudolf Stadler et al. profile →

Peers

Countries citing papers authored by Rudolf Herbst

Since Specialization

Citations

This map shows the geographic impact of Rudolf Herbst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rudolf Herbst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rudolf Herbst more than expected).

Fields of papers citing papers by Rudolf Herbst

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rudolf Herbst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rudolf Herbst. The network helps show where Rudolf Herbst may publish in the future.

Co-authorship network of co-authors of Rudolf Herbst

This figure shows the co-authorship network connecting the top 25 collaborators of Rudolf Herbst. A scholar is included among the top collaborators of Rudolf Herbst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rudolf Herbst. Rudolf Herbst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical course of Merkel cell carcinoma: A DeCOG multicenter study of 1049 patients 2025 ·European Journal of Cancer ·Georg Lodde, Ulrike Leiter, Anja Gesierich, Thomas Eigentler, (unknown), Claudia Pföhler, Thilo Gambichler, Rudolf Herbst, Friedegund Meier, Jessica C. Hassel, Frank Meiß, Peter Mohr, Patrick Terheyden, Georgios Nikolakis, Markus Hecht, Andreas Stang, (unknown), (unknown), Selma Ugurel, Jürgen C. Becker	1
2	LBA45 Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma: Long-term OS and final PFS results of the randomized phase II ImmunoCobiVem trial 2024 ·Annals of Oncology ·(unknown), (unknown), Lidija Kandolf Sekulović, Friedegund Meier, Thomas Eigentler, Mirjana Ziemer, (unknown), Anja Gesierich, Rudolf Herbst, Katharina C. Kähler, Dimitrios C. Ziogas, Željko Mijušković, Marlene Garzarolli, Christine Garbe, Alexander Roesch, (unknown), (unknown), (unknown), (unknown), (unknown)	1
3	1168P Tumor PD-L1 predicts the outcome of PD-1-based immunotherapy in metastatic melanoma depending on the type of tissue examined 2023 ·Annals of Oncology ·(unknown), Martin Kimmig, Klaus Griewank, Eva Hadaschik, Rudolf Herbst, (unknown), Jochen Utikal, Claudia Pfoehler, Jens Ulrich, Alexander Kreuter, Peter Mohr, Ralf Gutzmer, Friedegund Meier, Edgar Dippel, Julia Welzel, Jürgen C. Becker, Michael Weichenthal, Alpaslan Tasdogan, Dirk Schadendorf, (unknown)	1
4	Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma – An analysis of the prospective skin cancer registry ADOREG 2023 ·European Journal of Cancer ·(unknown), (unknown), Lisa Zimmer, Selma Ugurel, Friedegund Meier, Jochen Utikal, Claudia Pföhler, Rudolf Herbst, Sebastian Haferkamp, Julia Welzel, (unknown), Ulrike Leiter, Michael Weichenthal, (unknown), (unknown), Ralf Gutzmer	2
5	Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers 2021 ·Frontiers in Immunology ·Christian D. Sadik, Ewan A. Langan, Ralf Gutzmer, (unknown), Carmen Loquai, Lydia Reinhardt, Friedegund Meier, Daniela Göppner, Rudolf Herbst, Detlef Zillikens, Patrick Terheyden	28
6	Final analysis of DECOG-SLT trial: Survival outcomes of complete lymph node dissection in melanoma patients with positive sentinel node. 2018 ·Journal of Clinical Oncology ·Ulrike Leiter, Rudolf Stadler, Cornelia Mauch, Werner Hohenberger, Norbert H. Brockmeyer, Carola Berking, Cord Sunderkötter, Martin Kaatz, Kerstin Schatton, Percy Lehmann, Thomas Vogt, Jens Ulrich, Rudolf Herbst, Wolfgang Gehring, Jan‐Christoph Simon, Ulrike Keim, Peter Martus, Claus Garbe	15
7	Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma 2015 ·PLoS ONE ·Lisa Zimmer, Julia Vaübel, Peter Mohr, Axel Hauschild, Jochen Utikal, Jan C. Simon, Claus Garbe, Rudolf Herbst, Alexander Enk, Eckhart Kämpgen, Elisabeth Livingstone, Leonie Bluhm, Rainer Rompel, Klaus Griewank, Michael Fluck, Bastian Schilling, Dirk Schadendorf	181
8	Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: An open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study 2012 ·European Journal of Cancer ·Jean‐Jacques Grob, Thomas Jouary, Brigitte Dréno, Julien Asselineau, Ralf Gutzmer, Axel Hauschild, M.‐T. Leccia, Michael Landthaler, Claus Garbe, B. Sassolas, Rudolf Herbst, B. Guillot, Geneviève Chêne, Hubert Pehamberger	27
9	Disseminated Hyperkeratotic and Granulomatous Nodules in a Child with Fatal Epstein–Barr‐Virus–Associated Hemophagocytic Lymphohistiocytosis 2006 ·Pediatric Dermatology ·Thomas Brinkmeier, (unknown), Dieter Metze, Peter J. Frosch, Rudolf Herbst	4
10	Allergic and non‐allergic periorbital dermatitis: patch test results of the Information Network of the Departments of Dermatology during a 5‐year period 2004 ·Contact Dermatitis ·Rudolf Herbst, Wolfgang Uter, C. Pirker, Johannes Geier, Peter J. Frosch	65
11	Furunkul�re L�sionen am Stamm nach einer Mittelamerikareise 2004 ·Der Hautarzt ·(unknown), Thomas Brinkmeier, (unknown), Egbert Tannich, (unknown), Peter J. Frosch, Rudolf Herbst	1
12	Surgical pearl: ligation of the base of pyogenic granuloma—an atraumatic, simple, and cost-effective procedure 2003 ·Journal of the American Academy of Dermatology ·(unknown), Peter J. Frosch, Rudolf Herbst	5
13	Histologische Diagnose der Onychomykose 2003 ·JDDG Journal der Deutschen Dermatologischen Gesellschaft ·Rudolf Herbst, Thomas Brinkmeier, Peter J. Frosch	9
14	Absence of HHV‐8 DNA in hobnail hemangiomas 2002 ·Journal of Cutaneous Pathology ·Ralf Gutzmer, (unknown), Rudolf Herbst, Alexander Kapp, Peter Kiehl	5
15	Identification of two distinct deletion targets at 11q23 in cutaneous malignant melanoma 1999 ·International Journal of Cancer ·Rudolf Herbst, Ralf Gutzmer, (unknown), Susanne Mommert, (unknown), Alexander Kapp, (unknown)	32
16	Unilateral laterothoracic exanthem (asymmetrical periflexural exanthem of childhood): Report of an adult patient 1997 ·Journal of the American Academy of Dermatology ·Ralf Gutzmer, Rudolf Herbst, Peter Kiehl, Alexander Kapp, Jürgen Weiß	17
17	Allergic contact dermatitis from ophthalmics: update 1997 1997 ·Contact Dermatitis ·Rudolf Herbst, Howard I. Maibach	22
18	Mutation and Expression of TP53 in Malignant Melanomas 1995 ·Recent results in cancer research ·Johannes M. Weiss, (unknown), Karen C. Arden, (unknown), Henryk Pilch, Rudolf Herbst, E. G. Jung	42
19	Point mutations and allelic loss in the TP53 locus of cutaneous malignant melanomas 1994 ·Archives of Dermatological Research ·Johannes M. Weiss, Webster K. Cavenee, Rudolf Herbst, E. G. Jung, Karen C. Arden	11
20	Angiographie der Nieren 1958 ·Thieme eBooks ·(unknown), Rudolf Herbst, (unknown)	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact